Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

BridgeBio Pharma (2CL) Stock Price & Analysis

2CL Stock Chart & Stats

€67.54€0.88(1.32%)
At close: 5:30 PM GMT+1
€60€65€7010 Aug25 Aug8 Sep21 Sep6 Oct16 Oct2 Nov
Day’s Range
EUR 66.73 - EUR 67.54
52-Week Range
EUR 52.42 - EUR 78.90
Previous Close
EUR 66.66
Volume
N/A
Average Volume (3M)
43
Market Cap
EUR 13.05B
Enterprise Value
EUR 15.72B
Total Cash (Recent Filing)
EUR 1.54B
Total Debt (Recent Filing)
EUR 2.49B
Price to Earnings (P/E)
―
Beta
0.59
Next Earnings
Feb 25, 2027 (Est.)
EPS Estimate
-0.53
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Gross Margin

Strong revenue growth combined with very high gross margins indicates attractive product economics and meaningful commercial traction. If these characteristics persist, BridgeBio can convert growing product adoption into greater operating leverage as launch investments mature and fixed costs are spread across a larger revenue base.

Attruby Commercial Momentum

Attruby’s rapid year-over-year and sequential growth, supported by expanding physician adoption and stable gross-to-net, persistency, and compliance rates, strengthens BridgeBio’s commercial foundation. Continued uptake could provide a durable revenue engine to fund pipeline development and future launches.

Near-Term Product Launches

A concentrated sequence of potential launches gives BridgeBio multiple opportunities to diversify beyond Attruby and expand its rare-disease franchise. Priority review and defined regulatory dates improve planning visibility, while successful approvals could broaden revenue sources and strengthen its market position.

Bears Say

Persistent Cash Burn

Substantial operating and free-cash-flow deficits show that BridgeBio remains dependent on its cash resources while funding development and commercialization. Continued burn reduces financial flexibility over time and makes progress toward sustainable profitability important, even as reported losses have improved.

Ongoing Operating Losses

BridgeBio’s expected losses remain large despite improvement from the prior year, reflecting the cost of supporting Attruby and several launches simultaneously. The business therefore still depends on revenue growth and execution to absorb expenses, with profitability not expected to become broadly established until later.

Unpenetrated Prescriber Base

Attruby still needs to convert a large population of untried prescribers, many of whom are lower-volume or outside cardiology. This creates a lasting execution challenge: broader adoption may require additional education and commercial investment while competitors actively target the same expansion opportunity.

BridgeBio Pharma News

2CL FAQ

What was BridgeBio Pharma’s price range in the past 12 months?
BridgeBio Pharma lowest stock price was €52.42 and its highest was €78.90 in the past 12 months.
What is BridgeBio Pharma’s market cap?
BridgeBio Pharma’s market cap is €13.05B.
When is BridgeBio Pharma’s upcoming earnings report date?
BridgeBio Pharma’s next earnings report is estimated for Feb 25, 2027 (not yet confirmed), which is in 114 days.
How were BridgeBio Pharma’s earnings last quarter?
BridgeBio Pharma released its earnings results on Oct 29, 2026. The company reported -€0.376 earnings per share for the quarter, beating the consensus estimate of -€0.485 by €0.109.
Is BridgeBio Pharma overvalued?
According to Wall Street analysts BridgeBio Pharma’s price is currently Undervalued.
Does BridgeBio Pharma pay dividends?
BridgeBio Pharma does not currently pay dividends.
What is BridgeBio Pharma’s EPS estimate?
BridgeBio Pharma’s EPS estimate is -0.53.
How many shares outstanding does BridgeBio Pharma have?
BridgeBio Pharma has 194,800,780 shares outstanding.
What happened to BridgeBio Pharma’s price movement after its last earnings report?
BridgeBio Pharma reported an EPS of -€0.376 in its last earnings report, beating expectations of -€0.485. Following the earnings report the stock price went up 3.525%.
Which hedge fund is a major shareholder of BridgeBio Pharma?
Hedge funds hold BridgeBio Pharma shares: the largest hedge-fund position in BridgeBio Pharma is 2,055,705,921 shares, and hedge funds decreased their holdings by 1.4M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology